Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

被引：0
|
作者：
Carla L. Alves
Sidse Ehmsen
Mikkel G. Terp
Neil Portman
Martina Tuttolomondo
Odd L. Gammelgaard
Monique F. Hundebøl
Kamila Kaminska
Lene E. Johansen
Martin Bak
Gabriella Honeth
Ana Bosch
Elgene Lim
Henrik J. Ditzel
机构：
[1] University of Southern Denmark,Department of Cancer and Inflammation Research, Institute of Molecular Medicine
[2] Institute of Clinical Research,Department of Oncology
[3] Odense University Hospital,St. Vincent’s Clinical School, Faculty of Medicine
[4] Garvan Institute of Medical Research,Division of Oncology and Pathology, Department of Clinical Sciences
[5] University of New South Wales Sydney,Department of Pathology
[6] Lund University,undefined
[7] Sydvestjysk Sygehus,undefined
[8] Academy of Geriatric Cancer Research (AgeCare),undefined
[9] Odense University Hospital,undefined
来源：
Nature Communications | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors
    Droste, Annika
    Schmidt, Marcus
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [22] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Kappel, Coralea
    Elliott, Mitchell J.
    Kumar, Vikaash
    Nadler, Michelle B.
    Desnoyers, Alexandra
    Amir, Eitan
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [23] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Coralea Kappel
    Mitchell J. Elliott
    Vikaash Kumar
    Michelle B. Nadler
    Alexandra Desnoyers
    Eitan Amir
    Scientific Reports, 14
  • [24] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
  • [25] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [26] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [27] Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
    Gomes, Ines
    Gallego-Paez, Lina M.
    Jimenez, Maria
    Santamaria, Patricia G.
    Mansinho, Andre
    Sousa, Rita
    Abreu, Catarina
    Suarez, Eva Gonzalez
    Costa, Luis
    Casimiro, Sandra
    CELL REPORTS MEDICINE, 2023, 4 (08)
  • [28] ASCO 2019: Metastatic Breast Cancer - First OS Benefit with CDK4/6-Inhibitor plus endocrine Therapy
    Emrich, Gerhard
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (10) : 537 - 538
  • [29] Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia
    Jenneman, Dakota
    Zhong, Xiaojun
    Ma, Junjie
    Sun, Weihong
    Han, Heather
    Soliman, Hatem
    Loftus, Loretta
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Czerniecki, Brian
    Lee, M. Catherine
    Kiluk, John
    Khakpour, Nazanin
    Hoover, Susan
    Laronga, Christine
    Khong, Hung T.
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Effect of Tasurgratinib FGFR1-3 selective inhibitor on resistance to CDK4/6 inhibitor/endocrine therapy in breast cancer
    Kawano, Satoshi
    Fukushima, Sayo
    Nishibata, Kyoko
    Gejima, Ryu
    Watanabe, Saori
    CANCER SCIENCE, 2025, 116 : 1734 - 1734
12345